Abstract
Whether a biologic response modifier or triple disease-modifying antirheumatic drug (DMARD) therapy should be the mainstay of treatment for patients with rheumatoid arthritis (RA) is a subject for debate. This article compares triple conventional DMARD therapy versus biologic agents for the treatment of RA.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
